Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
| Autor: | Shai Shimony, Yiwen Liu, Yannis K. Valtis, Jonathan D. Paolino, Andrew E. Place, Andrew M. Brunner, Lachelle D. Weeks, Lewis B. Silverman, Lynda M. Vrooman, Donna S. Neuberg, Richard M. Stone, Daniel J. DeAngelo, Marlise R. Luskin |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Blood Advances. 7:1092-1102 |
| ISSN: | 2473-9537 2473-9529 |
| DOI: | 10.1182/bloodadvances.2022008280 |
| Popis: | Nelarabine, an antimetabolite prodrug, is approved as monotherapy for children and adults with relapsed and refractory T-cell acute lymphoblastic leukemia and lymphoma (R/R T-ALL/LBL), although it is often used in combination regimens. We sought to understand differences in efficacy and toxicity when nelarabine is administered alone or in combination. We retrospectively analyzed 44 consecutive patients with R/R T-ALL/LBL; 29 of whom were treated with combination therapy, most with cyclophosphamide and etoposide (23, 79%) and 15 with monotherapy. The median age was 19 years (range, 2-69), including 18 children ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|